IFP Advisors Inc Has $162,000 Holdings in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)

IFP Advisors Inc grew its stake in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) by 21.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 40,416 shares of the company’s stock after acquiring an additional 7,083 shares during the quarter. IFP Advisors Inc owned 0.47% of Citius Pharmaceuticals worth $162,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Geode Capital Management LLC increased its stake in shares of Citius Pharmaceuticals by 14.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,878,953 shares of the company’s stock valued at $941,000 after acquiring an additional 232,656 shares during the last quarter. Chelsea Counsel Co. increased its stake in shares of Citius Pharmaceuticals by 9.8% in the 3rd quarter. Chelsea Counsel Co. now owns 281,300 shares of the company’s stock valued at $141,000 after acquiring an additional 25,000 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of Citius Pharmaceuticals in the 3rd quarter valued at about $50,000. Miller Investment Management LP increased its stake in shares of Citius Pharmaceuticals by 99.3% in the 3rd quarter. Miller Investment Management LP now owns 99,640 shares of the company’s stock valued at $50,000 after acquiring an additional 49,640 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in shares of Citius Pharmaceuticals in the 3rd quarter valued at about $47,000. 16.88% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on CTXR. D. Boral Capital reaffirmed a “buy” rating and issued a $9.00 price target on shares of Citius Pharmaceuticals in a research note on Tuesday, February 18th. HC Wainwright reissued a “buy” rating and set a $100.00 target price on shares of Citius Pharmaceuticals in a research note on Tuesday, November 12th.

Citius Pharmaceuticals Price Performance

NASDAQ CTXR opened at $1.56 on Tuesday. The business has a 50 day simple moving average of $2.94 and a 200 day simple moving average of $7.09. Citius Pharmaceuticals, Inc. has a 52-week low of $1.47 and a 52-week high of $26.75.

Citius Pharmaceuticals (NASDAQ:CTXR) last posted its earnings results on Friday, February 14th. The company reported ($1.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.25) by ($0.05). Equities analysts expect that Citius Pharmaceuticals, Inc. will post -4.5 earnings per share for the current fiscal year.

Citius Pharmaceuticals Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.